Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits

Reuters

06-30

Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits

Avadel Pharmaceuticals plc is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right $(CVR)$ to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2547093754"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547093754\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2547093754?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547093754","market":"fut","top_or_hot":-1,"title":"Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AVDL\">Avadel Pharmaceuticals plc</a> is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-30 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AVDL\">Avadel Pharmaceuticals plc</a> is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a> to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL9gQVY3:1","article_id":"2547093754","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547093754","pubTimestamp":1751281269,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avadel Pharmaceuticals plc is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right  to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4532":"文艺复兴科技持仓","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","AVDL":"Avadel Pharmaceuticals plc","JAZZ":"爵士制药","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"Avadel Pharmaceuticals的或有价值权利可能从Jazz Pharmaceuticals诉讼中获得超过10亿美元的收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVDL":0.9,"JAZZ":0.9},"content_text":"Avadel Pharmaceuticals' Contingent Value Rights Could Yield Over $1 Billion from Jazz Pharmaceuticals Lawsuits\n    \n\nAvadel Pharmaceuticals plc is currently involved in six lawsuits against Jazz Pharmaceuticals, Inc., with potential settlements being a focal point for the company. The litigation could significantly impact Avadel's financial landscape, with the company's CEO suggesting that just one of these lawsuits, set to go to trial in four months, could yield a recovery exceeding $1 billion. In light of these legal proceedings, Avadel plans to distribute a contingent value right $(CVR)$ to its shareholders, entitling them to any proceeds from these lawsuits. This development comes amidst calls from a significant shareholder, ASL Strategic Value Fund, for Avadel's shareholders to vote against the current director nominees at the upcoming annual meeting, citing a need for a new strategic direction to enhance shareholder value.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avadel Pharmaceuticals plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250627862428) on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}